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Colonization of the oral and pharyngeal regions by Cundidu 
spp., particularly C. ulbicuns, is extremely common in hu- 
mans, particularly in early and late life. A variety of local and 
systemic conditions predispose the transformation of the 
benign colonization to a pathological state, which may have 
severe local or serious systemic consequences. The finding of 
oropharyngeal candidosis in an older patient, therefore, mer- 
its investigation of the likely host factors responsible for the 
organism adopting its pathogenic behavior. This paper pro- 
vides non-dental clinicians managing older patients a review 
of the clinical characteristics, risk factors, diagnosis, and 
management of oropharyngeal candidosis in older adults. J 
Am Geriatr SOC 45:863-870, 1997. 
ormally commensal organisms of the mouth, Cundidu N sp are responsible for the most common oral mucosal 
lesions reported in humans, especially in early and late life.’ 
The lesions of oropharyngeal candidosis, usually caused by 
C. ulbicuns and less commonly by C. glubrutu and C. tropi- 
culis, are reported in as many as 63% of otherwise healthy 
denture-wearing adults’ and more than 70% of denture- 
wearing adults residing in hospice or long-term care facili- 
In the absence of lesions, C. ulbicuns has been identi- 
fied in the saliva or within the oral cavities of 45% of healthy 
newborns,’ 45 to 65% of healthy children,6 and 30 to 45% of 
healthy  adult^.^^^ Rates of yeast carriage are somewhat 
higher, 50 to 65%, for patients who use removable dentures7 
and are highest (65-88%) among those of advanced age 
residing in acute and long-term care facil i t ie~.~>~-” 
Although candidosis is generally innocuous in otherwise 
healthy individuals, in patients with compromised immune 
defenses the infection can spread through the bloodstream or 
upper digestive system, causing mucosal ulcerations and even 
death. Systemic candidosis, which is caused by C. ulbicuns 60 
to 75% of the time, has been documented as a serious 
problem for patients receiving cytotoxic antineoplastic che- 
motherapy, in which it accounts for 70-80% of fungal 
infections. l 2  Candidemia in these patients carries a mortality 
rate of 71 to 79%.13 
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In the oral cavity and oropharynx, Cundidu lesions can 
present with a variety of appearances, and may appear either 
with or without symptoms. Yet even the most circumscribed 
lesion represents a transformation of the normally commen- 
sal organism to a pathogenic form capable of not only a local 
but a disseminated effect as well. This change from commen- 
salism to pathogen is imperfectly understood. Cundidu is 
opportunistic, transforming itself in response to changes in 
the complex of physical, biochemical, and biological factors 
that are loosely referred to as host defense.I4 Because the 
signs and symptoms of oropharyngeal candidosis in an older 
patient may be closely related to serious underlying systemic 
problems, and because the oral disease has the potential for 
systemic dissemination and serious morbidity, all such lesions 
merit focused diagnostic and therapeutic attention. 
This paper provides non-dental clinicians managing 
older patients a review of the clinical characteristics, risk 
factors, diagnosis, and treatment of oropharyngeal candido- 
sis in older adults. Throughout we will employ the term 
cundidosis rather than the equivalent but technically incor- 
rect term cundidiusis, inasmuch as the suffix -0sis is generally 
used for fungal disease (e.g., “aspergillosis”) whereas the 
suffix -iusis is generally customary for parasitic ones (e.g., 
“amoebiasis”). A third common term for the conditions 
concerning this paper, moniliusis, will also not be used here 
because it derives from a century-old but now corrected 
taxonomic error that initially placed Cundidu sp and Monifiu 
sp (organisms found in plants and rotting wood) in the same 
genus. ’’ 
CLINICAL PRESENTATION 
Oropharyngeal candidosis can have a number of differ- 
ent clinical presentations in the older individual. Oropharyn- 
geal candidosis can be divided into acute pseudomembra- 
nous, acute atrophic, chronic hyperplastic, and chronic 
atrophic candidosis, and median rhomboid glossitis and an- 
gular cheilitis (Table 1). It is important to note that an 
oropharyngeal candidosis in a patient may present as more 
than just one type of lesion. 
Acute pseudomembranous candidosis, often called 
thrush, has been well known since antiquity and represents 
about 30% of the clinical cases reported.” It is most preva- 
lent in infancy, in older people, in diabetics, patients with 
HIV/AIDS, leukemics, and among the terminally It may 
be seen secondary to the use of steroid aerosol inhalers,” 
psychotropic and other hyposalivation-inducing drugs,3 as 
well as in patients receiving radiation for head and neck 
tumors.” It is characterized intraorally and pharyngeally by 
discrete white patches on the surfaces of the labial and buccal 
mucosa, hard and soft palate, periodontal tissues, tongue, 
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Table 1. The Lesions of Oropharyngeal Candidosis 
Diagnosis Clinical Findings 
Acute pseudomembranous candidosis 
(“thrush”) 
Acute atrophic candidosis 
Chronic hyperplastic candidosis 
(“candidal leukoplakia”) 
Chronic atrophic candidosis 
(“denture stomatitis”) 
Median rhomboid glossitis 
Angular cheilitis (“perleche”) 
Asymptomatic. Discrete white, raised patches that can 
be wiped off with gauze or tongue blade, leaving an 
erythematous or bleeding base. Candidal nature can 
be confirmed through microscopic examination and 
KOH stain, but clinical appearance is pathognomic. 
Burning sensation in mouth or tongue. Tissues bright 
red; if tongue is involved there may be localized or 
generalized loss of filiform papillae. 
Asymptomatic. Discrete, raised whitish lesions that 
range from barely palpable to hard and rough. 
Generally on buccal mucosa or lateral tongue; less 
commonly, floor of mouth, ventral tongue, or oral 
labial mucosa. 
persistent salty taste. Localized or generalized 
erythema and edema, usually of maxillary alveolus 
and hard palate, limited to area covered by denture. 
Erythema may be pinpoint, generalized, or 
associated with hyperplastic, papillary nodules of 
the palate or palatal surface of the maxillary 
alveolus that bleed easily. 
Often asymptomatic or associated with vague 
complaints of an aching tongue. Raised, whitish, 
depapillated rectangular area in midline and 
midsection of tongue. 
Asymptomatic, itching, or painful; bleeds on wide 
opening of mouth. Erythematous fissuring at one or 
both corners of mouth: pale central area of serous 
transudate, surrounded by raised, reddened or 
speckled periphery. 
Asymptomatic or burning or itching; sometimes 
and oropharynx. The patches may coalesce to form conflu- 
ent, curd-like plaques. When these plaques are rubbed off by 
gauze or tongue blade, often with little difficulty, the under- 
lying base is raw, erythematous, and may bleed easily.” The 
undisturbed lesion is not normally painful. 
Acute atrophic candidosis is usually associated with a 
burning sensation in the mouth or on the tongue. The affected 
tissues may be bright red (Figure 1A); if the tongue is in- 
volved, there may be localized or generalized loss of the 
filiform papillae, and the denuded area appears distinctly 
glossy. The clinical appearance is indistinguishable from that 
arising in reaction to antibiotics or attributable to certain 
avitaminoses. This is a lesion in which the role of Cundidu 
infection is not fully understood: some contend that Cundi- 
du’s presence is only indicative of secondary invasion.’’ 
Chronic hyperplastic candidosis features discrete, raised 
lesions that vary from small, translucent, barely palpable, 
whitish areas to dense opaque plaques that are hard and 
rough to the touch. The lesions usually occur on the buccal 
mucosa or lateral borders of the tongue (Figure 1B) and can 
only be scraped off with great difficulty. The lesions are 
sometimes termed Cundidul leukoplakia, may be considered 
premalignant, and are associated with tobacco smoking.” 
Yet Cundidu species are not always associated with oral 
leukoplakia, and some studies suggest the occurrence of the 
organism in conjunction with a premalignant, hyperplastic 
lesion should be regarded as a complicating factor and not a 
causative one.’>’’ 
Chronic atrophic candidosis, also referred to as denture 
stomatitis or denture sore mouth, is regarded as the most 
common form of oropharyngeal infection by Cundidu species 
in older adults. Denture stomatitis is characterized by local- 
ized or generalized chronic erythema and edema of the tissues 
that are covered by a removable prosthesis. Lesions vary from 
mild hyperemic petechiae, to a generalized mild or moderate 
inflammatory reaction over the entire denture bearing area of 
the upper jaw (Figure lC) ,  to a severe inflammatory reaction 
of the mucosa with the formation of highly vascularized, 
papillary nodules (usually in the center and anterior portions 
of the hard palate: Figure 1D). Lesions of denture stomatitis 
are usually confined to the palate and upper jaw but may 
affect the mandibular tissues. Lesions are usually painless but 
some individuals experience slight soreness. If present, hyper- 
plastic papillary nodules may ooze blood when lightly 
rubbed. 
Median rhomboid glossitis is a chronic, elevated, sym- 
metrical area of hypoplasia or atrophy of the filiform papillae 
on the tongue dorsum anterior to the circumvallate papillae. 
Biopsy of median rhomboid glossitis lesions reveals candidal 
hyphae in more than 85% of cases.I5 
Angular cheilitis, also termed perleche, is an erythema- 
tous fissuring at  one or both corners of the mouth. The center 
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Figure l.(a) Acute atrophic candidosis associated with cyclosporine use (photograph provided by Dr. Randy Huffines); (b) Chronic 
hyperplastic candidosis on dorsolateral tongue of patient with a 100+ pack-year history of cigarette smoking. Biopsy reveals 
hyperkeratosis without dysplasia; (c) Chronic atrophic candidosis, mildest form; (d) Chronic atrophic candidosis, most severe form 
(photograph provided by T. Bloem). 
of the lesion is usually white, denuded, and weeping. The 
periphery may be raised and reddened or speckled. The lesion 
can be asymptomatic, itching, or painful, and commonly 
bleeds when the patient opens the mouth wide. Angular 
cheilitis may occur in isolation, but it is usually associated 
with an intraoral candidal infection. In older patients, the 
tendency for the lesion is worsened by the chronically moist 
environment that comes from facial wrinkling both at the 
corners of the mouth and along the nasolabial fold. This is 
frequently worse in patients who are long-term denture wear- 
ers, as the gradual resorption of the bone on which the 
dentures rest reduces the height of the lower face when the 
mouth is closed. Cheilitis lesions are often superinfected with 
Staphylococcus epidermidis;20 they have also been linked to 
riboflavin deficiency.2' 
RISK FACTORS 
Yeasts are normal members of the intraoral microflora in 
a substantial proportion of the population. Yet under certain 
conditions (Table 2) the opportunistic organisms become 
virulent in response to changes in the oral environment 
and/or a decreased defensive capability of the host. Oropha- 
ryngeal candidosis may come about as a result of dentures, 
use of certain medications, changes in the saliva, damage to 
the epithelial barrier, or impairment in immunity attributable 
to disease state or therapy. The compounding of two or more 
of these predisposing factors, as is often the case with a frail 
older patient, may further increase the probability of the 
individual developing an overt infection and complicate man- 
agement and resolution of the condition once it occurs. 
The presence of dentures -complete or partial -provides 
Cundidu with both a compatible surface on which to grow 
and a sheltered, favorable environment in which to thrive. 
Studies have consistently demonstrated greater presence of 
yeast among denture  wearer^,^,',^^-^^ as well as a higher 
prevalence of candidosis2,' compared with non-denture- 
wearing, age-matched controls. 
The presence of a denture, even a removable partial 
denture, creates a local microenvironment between the pros- 
thesis and the underlying tissue. Flow from minor salivary 
glands and the free exchange of oxygen with the rest of the 
mouth are impeded by the presence of the denture. The 
resulting low pH, anaerobic environment favors the growth 
of Cundidu and other saprophytic organisms. Cundidu has an 
affinity for the intaglio (tissue-fitting) surface of dentures and 
adheres to salivary proteins on the pro~thesis.~' Cultures 
taken from patients with oropharyngeal candidal infections 
consistently show greater colonization of the intaglio surface 
by Cundidu than of the tissue surface itself." Failure to 
remove the denture pellicle through thorough daily hygiene 
practices increases the likelihood for attachment of an infec- 
tious microflora that includes Cundidu species. Similarly, 
wearing dentures throughout a 24-hour period and removing 
them only briefly for cleaning, as approximately 75% of 
----___ ___ - JULY 1997-VOL. 45, NO. 7 JAGS 866 SHAYETAL. 
Table 2. Predisposing Factors for Oropharyngeal Candidosis 
Factors Comments 
Local factors 
Denture use 
Salivary hypofunction 
Headheck irradiation 
Topical corticosteroids 
Systemic factors 
Medication use 
Nutritional deficiency 
Immunodeficiency 
Hematological disorders 
Endocrinopathies 
Increased risk with poor oral care, poor fit, nocturnal use 
Most commonly due to medication use (ems., agents with 
Due to salivary gland destruction, mucositis 
Affects soft palate and posterior pharyngeal wall 
anticholinergic effects) 
Especially antibiotics, corticosteroids, cytotoxic agents 
Particularly the B vitamins 
Congenital, disease-related, or pharmacologically-induced 
Particularly leukemias, neutropenias, iron deficiency anemia, 
Most commonly diabetes mellitus; also hypofunctional 
myeloperoxidase deficiency of neutrophils 
states of thyroid, parathyroid, or adrenals 
denture patients do, correlates with higher candidal counts 
and increased prevalence of ~ a n d i d o s i s . ~ - ~ ~ ~ ~ ~ ~ ~ ~  M any den- 
ture patients experience physical irritation from dentures that 
do not fit the tissues accurately. Mechanical tissue trauma is 
considered to be a contributing factor in denture stomatitismZ6 
The use of medications can enhance fungal proliferation 
by altering the intraoral environment or by reducing host 
defenses. Medications associated with development of clini- 
cal candidosis include broad spectrum antibiotics, glucocor- 
ticosteroid preparations, and antisialogogue and immuno- 
suppressive agents. The use of broad spectrum antibiotics 
may result in suppression of the normal oral bacterial flora 
with an overgrowth of the endogenous candidal organisms, 
although the data supporting this widely-accepted mecha- 
nism are largely anecdotal.' It is currently believed that the 
action of antibiotics limits bacterial adherence to oral epithe- 
lium, thereby opening a broader niche for candidal coloniza- 
tion.I4 Steroid inhaler medications appear to lower mucosal 
resistance to Cundidu by locally suppressing both the nonspe- 
cific inflammatory and cell-mediated T-lymphocyte respons- 
es.'* Systemic steroid regimens also impair cellular immunity 
by an analogous mechanism." 
Saliva is critical for maintaining oropharyngeal health. It 
maintains a nearly neutral pH, contains the nonspecific anti- 
microbial factors lactoferrin, lysozyme, and lactoperoxidase, 
is an abundant source of secretory IgA and fungistatic histi- 
dine-rich polypeptide, and maintains epithelial health 
through epidermal growth factor and lubrication of the tis- 
sues with a variety of glycoproteins.'2,2* Alteration of the 
quality or quantity of saliva is potentially devastating to the 
health of the oral cavity and protection of the individual in 
general and specifically lowers host resistance to candidal 
infe~tion. '~ Yet an extremely common side effect of medica- 
tions is the modification of salivary flow and composition.28 
Agents with anticholinergic effects (e.g., anticholinergics, tri- 
cyclic antidepressants, neuroleptics, antihistaminics) create 
the most ~ o n c e r n . ~  A number of systemic disease states are 
also associated with diminished salivary flow and, thereby, 
with the development of oropharyngeal candidosis. In older 
patients, these include hypothyroidism, hypoadrenalism, and 
Sjogrens syndrome (SS).29 
During irradiation of the head and neck as treatment for 
malignancy, if 50% or more of one of the major salivary 
glands is in the field of radiation the patient will experience a 
significant and permanent decrease in saliva quantity and 
quality, rendering the mouth highly susceptible to fungal and 
bacterial  infection^.^' In a prospective study of 109 patients 
undergoing such treatment, cultures positive for Cundidu 
increased from 27% to 49% from pre-treatment to during 
treatment and increased further to 59% on follow up.I9 
In patients with diabetes, fungal infections may be more 
severe and complicated secondary to neutrophil suppres- 
 ion.^' Aly et al. have identified age, poor glycemic control, 
blood type, and the presence of dentures as factors that 
influence the oral carriage of yeast in the diabetic patient.32 
Hill et al.33 found that glycosylated hemoglobin greater than 
12 mg% was strongly associated with candidal infection. 
An individual's blood type may play a role in host 
susceptibility to candidal infections by influencing the ability 
of the organism to adhere to epithelial cells. Several hexoses 
and hexosamines have been identified as receptors for Cun- 
didu, and these glycocompounds are the immunodominant 
sugars of blood types. Denture stomatitis and plaque accu- 
mulation have been found to be statistically more severe and 
in greater quantity in patients of blood group 0 than the 
other ABO blood types in several studies.34 Tobacco smokers 
generally display higher candidal carriage and greater preva- 
lence of candidosis, probably related to the decrease in oral 
oxygenation and decreased oral leukocyte and oral immuno- 
globin concentration observed in  smoker^.^' 
Immunosuppressive agents such as azathioprine selec- 
tively suppress the T-lymphocyte system and increase host 
susceptibility to fungal  infection^.^^ Most antineoplastic cy- 
totoxic chemotherapy regimens cause a transient but serious 
diminution in immune system function. In one investigation, 
46.9% of 1500 patients treated for acute leukemias devel- 
oped chemotherapy-related oral complications, of which 
34.2% were oral infections and Cundidu the most frequently 
implicated path~gen.~'  Wahlin38 suggested that some of the 
increase in candidosis in leukemic patients was due to sali- 
vary suppression brought on by the cytotoxic chemotherapy. 
Adjuvant chemotherapy for solid tumors has a less common 
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but still serious effect, with 9.7% of patients contracting 
infections and Cundidu responsible for more than 70% of 
those  infection^.^^ 
Altered immunological states such as those seen in pa- 
tients with the human immunodeficiency virus render an 
individual extremely susceptible to colonization and the de- 
velopment of oropharyngeal candidosis.36 Primary immune 
deficiencies such as HIV, IgA deficiency, and lymphocytic and 
phagocytic dysfunction are typically accompanied by oro- 
pharyngeal or disseminated candidosis. It has been suggested 
that cellular factors are the primary mechanism of defense 
against oral mucocutaneous infections and that humoral 
factors are extensively involved in the containment and the 
prevention of systemic infections.”*4o Porter and Scully re- 
ported that candidosis infections were present in 25% of 39 
IgA-deficient patients ~ t u d i e d . ~ ’  
Finally, diet plays a multifactorial role in the develop- 
ment of oral candidal infections. Growth of Cundidu in saliva 
is enhanced by the presence of glucose. The adherence of the 
organism to oral epithelial cells is increased by a high carbo- 
hydrate diet.21 Correlations have been reported between low 
serum iron and folate concentrations and the development of 
candidal infections, particularly angular ~ h e i l i t i s . ~ ~  The sug- 
gested mechanism is a decreased lymphocytic response to 
Cundidu antigen in iron deficient states; responsivity is re- 
stored upon correction of the deficiency.’ Nutritional defi- 
ciencies, in general, can result in diminished integrity of the 
mucosal barrier and allow for increased candidal coloniza- 
tion. In addition to iron and folate, Vitamins B,, B2, B,, and 
C have been implicated as contributing to candidosis2’ by 
predisposing patients to candidal invasion of e p i t h e l i ~ m . ~ ~  
DIAGNOSIS 
The clinical presentation of oropharyngeal candidosis is 
frequently unambiguous, but laboratory testing is necessary 
to have a positive confirmation, to differentiate the lesion 
from lichen planus, benign mucous membrane pemphigoid, 
pemphigus, squamous cell carcinoma, or other mucosal le- 
sions, and to rule out a possible role of vitamin deficiency. 
Authors have suggested sampling for culture using swabs (on 
the tongue,24 throat,24 or d e n t ~ r e ~ . ~ ~ ) ,  sponges (on 
the t i s s ~ e s ~ ’ ~ ~  or on the denture7), rinses,” saliva,x*22*43 and 
dental impressions (of either the mouth’ or the inner surface 
of the But inasmuch as one-third to one-half of 
the population have Cundidu present in their oral cavities, 
positive cultures alone are inadequate for a diagnosis. Simi- 
larly, a negative culture or cytological smear does not defin- 
itively rule out a fungal cause, as illustrated by the widely 
variant findings obtained by comparisons of salivary cultures, 
oral rinse cultures, sponge imprints of tissue and denture, 
denture scrapings, and epithelial smears.2’7~’0”’*22 Quantity 
of candidal carriage correlates with infection, so a quantita- 
tive determination is necessary to delineate benign carriage 
from an infected state. Epstein et al. suggest patients rinse 
with phosphate buffered saline for 60 seconds and expecto- 
rate. When the expectorant is centrifuged, and the concen- 
trate pellet re-suspended and cultured on Sabouraud’s media 
for 48 to 72 hours at 35”C, growth 2 200 c f d m l  is indicative 
of infection rather than merely ~arriage.~’ 
Histological confirmation can be achieved with KOH, 
PAS, or H&E stains, but biopsies are prone to false negative 
results, particularly in chronic atrophic candidosis, where far 
greater fungal populations are found on the denture intaglio 
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surface than on the tissue.’ Exfoliative cytology can be ac- 
complished easily with a tongue blade firmly scraping the 
surface of a lesion. The material is then transferred to a slide, 
fixed with ethanol, and stained. Generally the presence of 
hyphal (filamentous) forms of C. ulbicuns among the epithe- 
lial cells is confirmatory for infection, but another (although 
less common) oral yeast, C. glubrutu, does not display a 
hyphal form even when pathogenic.” And the blastospore 
(budding) form of C. ufbicuns, while not a tissue invader like 
its hyphal form, may still be responsible for disease through 
noninvasive mechanisms (such as tissue reaction to metabo- 
l i te~) .~’  
In general, the clinical appearance of acute pseudomem- 
branous and chronic atrophic candidosis will be sufficient for 
diagnosis and initiation of treatment (described below). Cul- 
ture and sensitivity testing should be undertaken if initial 
therapy is unsuccessful. In contrast, acute atrophic and 
chronic hyperplastic forms may mimic other mucosal lesions, 
or those lesions may be complicated by candidal superinfec- 
tion. Biopsy is recommended, even as empiric therapy is 
initiated, to rule out multifactorial or more serious disease. 
MANAGEMENT 
Management of the patient with oral candidosis requires 
the identification and, if possible, concurrent resolution of 
underlying predisposing systemic conditions. In addition, the 
clinician must assess current medication use (to identify 
agents that either predispose the patient to the infection or 
might interact with the antifungal regimen), concurrent mu- 
cosal disorders (that may be treated with systemic steroids), 
use of oral prostheses, and the type, severity, and chronicity 
of the infection. 
Cases of oral candidosis that appear not to be compli- 
cated by systemic factors are generally managed through 
improvement of oral hygiene and the use of topical antifungal 
rinses on a schedule of four times a day for 2 weeks. Good 
oral hygiene consists of the care and cleaning of the dentition, 
soft tissue, tongue, and - most importantly - dentures, if 
present. If a patient wears dentures, dental referral is advis- 
able because modification of the dentures’ fit and function 
may be required. In any case, patients should be instructed to 
leave their dentures out overnight or for one extended period 
daily (at least 6 hours). The patient must be reminded to 
remove the denture while rinsing with the antifungal agent to 
permit contact between the medication and the mucosa. 
I t  is essential that the denture be cleaned and disinfected 
on a daily basis to prevent reinfection. Dentures have irregu- 
lar and porous surfaces to which Cundidu readily adheres and 
in which it can reside? protected from mechanical debride- 
ment such as brushing. A comparison of fungal contamina- 
tion of dentures cleaned by brushing and those soaked in a 
commercial enzyme-containing denture cleaning solution 
found that soaking alone was as effective in eliminating 
Cundidu as soaking and brushing and far more effective than 
brushing without soaking.47 Soaking the denture in a 0.12% 
chlorhexidine solution has been demonstrated to be effec- 
tive4* although soaking in nystatin solution is not.49 Disin- 
fection can also be accomplished by soaking the denture in a 
1:lO dilution of household bleach (although this approach 
should not be recommended for a metal-containing denture, 
as discoloration will result), commercial denture cleanser 
(alkaline peroxide),” or benzoic acid.’l Use of an ultrasonic 
cleaning tank with a suitable solution was shown by scanning 
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electron micrography to be more effective in removing debris 
and organisms than soaking alone.52 Air drying the denture 
also kills adherent yeast.s3 
Therapeutic agents whose indications and usage include 
the treatment of oral candidosis are listed in Table 3. The 
most commonly prescribed topical rinse is ny~tatin,’~ which 
is absorbed only sparingly through the GI tract, skin, and 
mucous membranes. Although repeated in vitro subculturing 
of C. ulbicuns exposed to nystatin has been shown to result in 
Table 3. Summary of Management Strategies for Oropharyngeal 
Candidosis 
Denture care 
Clean at least daily with running water and a brush 
specifically for cleaning dentures 
After brushing, soak daily for 20 minutes in a fresh 
solution of one of the following: 
0.1 2% chlorhexidine gluconate 
commercial denture cleanser (e.g., Polident@, 
1 :I0 solution of household b1each:water 
benzoic acid solution 
Efferdentm) 
Alternatively, place denture in one of the above solutions 
and run in ultrasonic cleaner 20 minutes 
Keep dentures out of mouth for at least 6 hours per day, 
preferably longer 
Allowing a brushed-clean denture to dry in air will also 
eradicate adherent fungi 
Have prostheses evaluated for proper tissue adaptation 
and occlusion by a dentist 
Topical agents (For all these agents, remove dentures 
before use of medicament, then thoroughly clean 
dentures before reinserting) 
Nystatin suspension (commercially prepared) 
100,00OU/mL in sucrose solution 5 mL QID, rinse 60 sec 
and spit or swallow. 
Nystatin suspension (extemporaneously prepared) 
100,00OU/mL (no sucrose) 5 mL QID, rinse 60 sec and 
spit or swallow. 
Nystatin oral troches. Suck until dissolved, TID/QID 
Nystatin vaginal suppositories. Suck until dissolved, 
TID/QID 
Chlorhexidine gluconate 0.12%. 15 mL BID rinse 60 
sec and spit 
Clotrimazole troches 10 mg. Suck until dissolved, 
4 -5 x/day 
Clotrimazole vaginal suppositories, suck until dissolved, 
1-3 x/day 
Systemic agents 
10 days) 
Care of intraoral mucosa 
Fluconazole tablets (100 mg first day; 50 mg QD for 
Ketoconazole tablets (200 mg TID for 10 days) 
Care of lip commissures (“angular cheilitis”) 
Nystatin ointment 100,000 U/g apply TID/QID 
Clotrimazole 1 YO cream apply TID/QID 
Clotrimazole 1 YO ointment apply TID/QID 
Ketoconazole 2% cream apply TID/QID 
Nystatin/diphenhydramine ointment apply TID/QID 
Nystatldttiamcinolone acetonide ointment apply TID/QID 
the development of nystatin-resistant isolates,55 other studies 
found no clinically significant emergence of resistance even in 
severely susceptible  patient^.'^ Prepared nystatin oral rinses 
customarily contain more than 50% sucrose to disguise a 
disagreeable taste. This can promote tooth decay in older 
patients with teeth, particularly those who suffer from sali- 
vary hypofunction, but a sugar-free nystatin rinse can be 
prepared by a pharmacist. Another option is for the dentate 
patient to suck on nystatin or clotrimazole vaginal supposi- 
tories, and a third option is to use one of the systemic agents 
described below. 
Nystatin is relatively ineffective if the candidosis is com- 
plicated by diabetes, steroid use, or an immunocompromised 
or immunosuppressed state. Clotrimazole troches are effec- 
tive for some cases that do not resolve with the use of 
nystatin5’ but share with nystatin the need for repeated 
dosages throughout the day and the disadvantage of high 
sugar content. For these reasons, the single dose per day of 
fluconazole has gained popularity in recent years, and itra- 
conazole, also prescribed for once-per-day dosing, shows 
promise as well.58 Ketoconazole is also highly effective, al- 
though drug interactions (see Table 4), hepatic effects, and 
the need for gastric acidity for proper absorption make it 
unsuitable for many geriatric cases. It has also been suggested 
that ketoconazole may be ineffective in patients with salivary 
hypofunction because the agent is secreted in the ~al iva.~’  
Clinical relapse following the chemotherapeutic man- 
agement of chronic atrophic candidosis is not uncommon. In 
many cases, this is probably caused by poor patient compli- 
ance with some aspect of the treatment regimen.56 Compli- 
ance can be compromised by: patients not experiencing dis- 
comfort and, therefore, not perceiving the need for the 
medication; the expense or disagreeable taste of the medica- 
tion; failure to remove the dentures when using the medica- 
tion; inadequately improved denture hygiene”; or failing to 
remove the prostheses for at least 6 hours each day. In the 
institutional setting, compliance may be compromised fur- 
ther by decreased patient cooperation, inability of the patient 
to retain the antifungal agent in the mouth, and lack of staff 
awareness of the necessity to remove and clean the denture 
Table 4. Potential Drug Interactions with Systemic Antifungals 
Interaction Ketoconazole Fluconazole 
~ 
Decreased circulating azole levels 
Antacids 
H, Blockers 
lsoniazid 
Rifampin 
Warfarin 
Cyclosporin 
Oral hypoglycemics 
Corticosteroids 
Theophylline 
Phenytoin 
Terfenadine 
Increased circulating levels of 
Decreased circulating levels of 
Decreased levels of azole and 
Cardiovascular reaction 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
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for each medication administration. If noncompliance is SUS- 
pected, the use of single dose per day systemic regimens and 
assistance with hygiene may be advisable. The concept that 
patients may reinfect themselves from other, non-oral body 
sites that are acting as candida reservoirs (e.g., nasolabial or 
inframammary folds) also has led some authors to advocate 
the use of systemic regimens over local therapy in recalcitrant 
cases.lS 
Antifungal steroid creams and ointments are useful for 
the treatment of angular cheilitis although any concurrent 
intraoral infection must be managed if the perioral lesion is to 
be resolved. Furthermore, the contribution of dietary defi- 
ciency should always be explored for findings of this lesion, 
even as topical treatment is initiated. The patient should 
apply the prescribed cream or ointment (nystatin, clotrim- 
azole, ketoconazole, or miconazole) to the infected area at 
least twice a day for 2 weeks. Empirically, these preparations 
have been suggested for cases of chronic atrophic candidosis, 
where the cream is placed on the intaglio surface of the 
denture. 
Chlorhexidine gluconate oral rinse can be effective in 
uncomplicated cases of oropharyngeal candidosis when ap- 
propriate attention is paid to denture hygiene.48 It can also be 
an appropriate adjunctive therapy to systemic antimycotic 
regimens. Kulak et al. found that fluconazole in conjunction 
with chlorhexidine gluconate for the treatment of simple 
denture stomatitis was better than management with flucon- 
azole alone or the remaking of the denture without medica- 
tion.'" Chlorhexidine should not be used in combination 
with nystatin rinse, however, as a reduction in the efficacy of 
both medications results." 
The potential morbidity of oropharyngeal candidosis in 
certain groups of immunosuppressed patients poses the pos- 
sibility for prophylaxis against fungal infection in these indi- 
viduals. Nystatin rinses have not been successful; despite 
prophylactic nystatin rinsing during conventional chemo- 
therapy and bone marrow transplantation, about one-third 
of leukemic patients develop oropharyngeal candidoskh2 
Neither nystatin rinse nor clotrimazole troches were effective 
in eliminating all incidences of candidosis in a series of 
immunosuppressed liver transplant patients.63 In contrast, 
prophylactic use of chlorhexidine rinse has been quite effec- 
tive. Ferretti et al. reported highly significant success with 
bone marrow transplant patients, in which cultivable Cun- 
didu was reduced and no infections were noted clinically 
when patients rinsed with chlorhexidine; nearly 70% of the 
control group developed oropharyngeal candidosis, and two 
died of systemic candid~ses. '~ Fluconazole was also found to 
be effective in a prophylactic regimen of 50 mg/day in a 
randomized, double-blind trial involving 112 patients with 
metastatic  neoplasm^.'^ Although equal proportions of both 
groups cultured positive for Cundidu at the outset of the 
study, only 3% of the fluconazole group but 54% of the 
controls developed acute pseudomembranous candidosis in 
the 4 weeks of the trial. 
Prophylactic antifungal treatment is less defensible for 
patients who are at high risk for uncomplicated oropharyn- 
geal candidosis but at  low risk for serious local and/or sys- 
temic spread. This includes otherwise healthy denture wear- 
ers, patients with drug-induced xerostomia, diabetics, and 
those about to undergo irradiation of the head and neck for 
treatment of malignancy. For these patients, the recom- 
mended care is prevention through oral and denture hygiene 
and periodic oral examinations followed by definitive treat- 
ment upon the discovery of fungal infection. 
New therapeutic agents as well as sustained delivery 
systems are under development and investigation. Incorpora- 
tion of amphotericin B powder into denture adhesive was not 
successful, possibly because of the amounts employed.66 Al- 
ternatively, inclusion of nystatin powder in a dentist-applied 
soft denture liner showed a sustained antifungal effect in 
~ i t r o . ~ ~  Preliminary work on the use of a rinse containing 
histidine-rich polypeptide (HRP) - a natural antifungal sub- 
stance in normal human saliva - revealed a reduction and/or 
elimination of C. ulbicuns from denture fitting surfaces.68 A 
mucosal oral therapeutic system (MOTS) designed to provide 
a sustained 2-hour release of nystatin using a controlled- 
release osmotic tablet has been found to be superior to 
nystatin pastilles.69 Miconazole-containing lacquer applied 
to the intaglio surface of a denture effectively reduces can- 
didal colonization, but current formulations have to be reap- 
plied freq~ently.~'  
SUMMARY 
Oropharyngeal candidosis is an extremely common oral 
infection, particularly among older adults. Its occurrence 
represents a local or systemic breakdown in normal host 
defenses, making its appearance an alarm that should not be 
ignored. Clinicians caring for older adults should be familiar 
with the clinical presentations of oropharyngeal candidosis, 
its signficance as a physical finding, and the range of manage- 
ment options available. 
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